RxDoctor Payments Data

Ricardo Celaya, MD

Internal Medicine · Phoenix, AZNPI 1861476095

Payments from drug & device makers

$2,117in general payments, 2019–2025

Across 87 payments — averaging $24.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$391
  • Amgen$183
  • Novo Nordisk$177
  • Pacira Pharmaceuticals Incorporated$121
  • Bayer$121
  • Merck$118
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$2,117100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,117 in reported general payments places this provider in the 85th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$41,098
Medicare patients
277
Services billed
845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide87$116,443
JardianceEmpagliflozin70$88,213
FarxigaDapagliflozin Propanediol49$41,756
OzempicSemaglutide32$34,332
MounjaroTirzepatide27$30,337
JanuviaSitagliptin Phosphate21$24,702
EliquisApixaban25$23,571
LantusInsulin Glargine,hum.Rec.Anlog21$6,138
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$6,114
Atorvastatin Calcium210$2,392
Albuterol Sulfate HfaAlbuterol Sulfate70$1,934
Gabapentin104$1,814
Omeprazole104$1,375
Metformin Hcl172$1,333
Nano 2nd Gen Pen NeedlePen Needle, Diabetic17$1,091

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$12$146,780114 claims
Boehringer IngelheimJardiance$42$88,21370 claims
AstraZenecaFarxiga$46$41,75649 claims
Novo NordiskOzempic$177$34,33232 claims
MerckJanuvia$118$24,70221 claims
PfizerEliquis$40$23,57125 claims
Sanofi-aventis U.S. LLCLantus$32$6,13821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →